We’re fiercely passionate in our belief that declining brain function is something that can be slowed or reversed. That’s why we are working tirelessly so that people living with or at risk for neurodegenerative diseases have a more hopeful future.
Frontotemporal dementia (FTD) is the most common dementia in individuals under 60. FTD affects roughly 50,000 to 60,000 individuals in the United States and roughly 110,000 individuals in the United Kingdom and European Union. We are searching for genetic treatments that target the dysfunctional brain immune system to slow the progression of FTD.
Alzheimer’s disease is an irreversible degenerative brain disease and the most common form of dementia. It slowly destroys memory and thinking skills, and eventually the ability to carry out the simplest tasks. We are approaching the treatment of Alzheimer’s disease and other neurodegenerative diseases in an entirely new way: by restoring the function of the brain’s innate immune system to maintain neurological function with the hope of one day halting, or possibly even reversing, the course of disease.
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s Disease or Motor Neuron Disease, is a rare neurodegenerative disease that affects up to 30,000 individuals in the United States and approximately 50,000 people in Europe. Mutations within multiple genes, including the C9orf72 gene, are believed to cause the disease.
Alector is committed to developing safe and effective therapies to transform the lives of patients with neurodegenerative diseases.